FY2024 EPS Estimates for ZVRA Reduced by Cantor Fitzgerald

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at Cantor Fitzgerald cut their FY2024 earnings estimates for Zevra Therapeutics in a report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($1.97) per share for the year, down from their previous forecast of ($1.61). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the company earned ($0.40) earnings per share.

Several other research firms have also recently commented on ZVRA. Roth Mkm raised their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Monday, September 30th. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 target price on the stock. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Maxim Group increased their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics presently has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

ZVRA stock opened at $8.97 on Monday. The firm has a market cap of $478.78 million, a PE ratio of -4.55 and a beta of 1.93. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a 50-day moving average price of $8.06 and a 200-day moving average price of $6.54. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.21.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC bought a new position in Zevra Therapeutics during the 2nd quarter valued at $474,000. Jacobs Levy Equity Management Inc. boosted its holdings in Zevra Therapeutics by 102.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after purchasing an additional 17,557 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in Zevra Therapeutics in the 3rd quarter worth about $833,000. Price T Rowe Associates Inc. MD purchased a new stake in Zevra Therapeutics in the 1st quarter valued at about $64,000. Finally, Vanguard Group Inc. lifted its position in shares of Zevra Therapeutics by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after buying an additional 58,866 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.